Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: Results of the lung oncology group in kyushu (LOGiK-0802)

Kazuhiko Yamada, Koichi Azuma, Masafumi Takeshita, Junji Uchino, Chinatsu Nishida, Takayuki Suetsugu, Akira Kondo, Taishi Harada, Hirofumi Eida, Junji Kishimoto, Goki Eriguchi, Koichi Takayama, Yoichi Nakanishi, Kenji Sugio

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: As the incidence of lung cancer in the elderly is increasing worldwide, there exists a need to develop a clinically effective, less toxic therapy for this patient population. Although erlotinib has shown proven effectiveness against non-small cell lung cancer (NSCLC), few studies have prospectively investigated its application to elderly patients. Patients and Methods: Patients aged 75 years with advanced or recurrent NSCLC including wild-type EGFR who had previously received one or two chemotherapy regimens were enrolled in this trial. Erlotinib was initially administered at a dose of 150 mg/day orally until disease progression or unacceptable toxicities occurred. The primary endpoint was the objective response rate. Results: Forty patients were enrolled between May 2009 and January 2014.

Original languageEnglish
Pages (from-to)2881-2887
Number of pages7
JournalAnticancer research
Volume36
Issue number6
Publication statusPublished - Jun 2016

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yamada, K., Azuma, K., Takeshita, M., Uchino, J., Nishida, C., Suetsugu, T., ... Sugio, K. (2016). Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: Results of the lung oncology group in kyushu (LOGiK-0802). Anticancer research, 36(6), 2881-2887.